Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations
- 1 August 2017
- journal article
- research article
- Published by Elsevier in European Journal of Cell Biology
- Vol. 96 (5) , 476-485
Abstract
No abstract availableKeywords
Funding Information
- Movember Foundation (2012-951, 2013-8)
- Canadian Institutes of Health Research
- Prostate Cancer Canada
- Santé (315690)
- Canadian Cancer Society (701590)
- Heart and Stroke Foundation of Canada
This publication has 44 references indexed in Scilit:
- Cell‐penetrating peptides: 20 years later, where do we stand?FEBS Letters, 2013
- The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer CellsJournal of Medicinal Chemistry, 2012
- Highly Potent Inhibitors of Proprotein Convertase Furin as Potential Drugs for Treatment of Infectious DiseasesJournal of Biological Chemistry, 2012
- Strategies to improve plasma half life time of peptide and protein drugsAmino Acids, 2006
- Abbreviated nomenclature for cyclic and branched homo‐ and hetero‐detic peptidesChemical Biology & Drug Design, 2005
- Proteases Universally Recognize Beta Strands In Their Active SitesChemical Reviews, 2005
- Proprotein Convertase Models based on the Crystal Structures of Furin and Kexin: Explanation of their SpecificityJournal of Molecular Biology, 2005
- Proprotein Convertases in Tumor Progression and MalignancyThe American Journal of Pathology, 2002
- Polyarginines Are Potent Furin InhibitorsJournal of Biological Chemistry, 2000
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973